Ong Y T, Kirby K A, Hachiya A, Chiang L A, Marchand B, Yoshimura K, Murakami T, Singh K, Matsushita S, Sarafianos S G
Christopher S. Bond Life Sciences Center, University of Missouri School of Medicine, Columbia, MO 65211, USA.
Cell Mol Biol (Noisy-le-grand). 2012 Dec 22;58(1):71-9.
KD-247 is a humanized monoclonal antibody that targets the third hypervariable (V3) loop of gp120. It can efficiently neutralize a broad panel of clade B, but not non-clade B, HIV-1 isolates. To overcome this limitation, we are seeking to prepare genetically-engineered single-chain variable fragments (scFvs) of KD-247 that will have broader neutralizing activity against both clade B and non-clade B HIV-1 isolates. Initial attempts of optimizing the expression of KD-247 scFv have resulted in the formation of insoluble protein. Therefore, we have established purification protocols to recover, purify, and refold the KD-247 scFv from inclusion bodies. The protocol involved step-wise refolding of denatured scFv by dilution, dialysis, and on-column nickel-affinity purification. Monomeric scFv was further purified by size-exclusion chromatography. Using far UV circular dichroism (CD) spectroscopy we confirmed the expected beta-sheet profile of the refolded KD-247 scFv. Importantly, the refolded KD-247 scFv showed neutralizing activity against replication-competent HIV-1 BaL and JR-FL Env pseudotyped HIV-1, at potency comparable to that of the native full-size KD-247 antibody. Ongoing studies focus on the application of this system in generating KD-247 scFv variants with the ability to neutralize clade B and non-clade B HIV-1 isolates.
KD - 247是一种靶向gp120第三高变区(V3环)的人源化单克隆抗体。它能有效中和多种B亚型HIV - 1分离株,但对非B亚型HIV - 1分离株无效。为克服这一局限性,我们正致力于制备KD - 247的基因工程单链可变片段(scFv),使其对B亚型和非B亚型HIV - 1分离株均具有更广泛的中和活性。最初优化KD - 247 scFv表达的尝试导致了不溶性蛋白的形成。因此,我们建立了从包涵体中回收、纯化和重折叠KD - 247 scFv的纯化方案。该方案包括通过稀释、透析和柱上镍亲和纯化对变性的scFv进行逐步重折叠。单体scFv通过尺寸排阻色谱进一步纯化。使用远紫外圆二色性(CD)光谱,我们确认了重折叠的KD - 247 scFv具有预期的β - 折叠结构。重要的是,重折叠的KD - 247 scFv对有复制能力的HIV - 1 BaL和JR - FL Env假型化HIV - 1显示出中和活性,其效力与天然全长KD - 247抗体相当。正在进行的研究聚焦于该系统在生成具有中和B亚型和非B亚型HIV - 1分离株能力的KD - 247 scFv变体中的应用。